Get started

Financials · ALT

Altimmune Inc. (ALT) financials

For fiscal 2025 (ended Dec 31, 2025), Altimmune Inc. reported $41.0K of revenue and -$88.09M of net income.

Revenue, FY2025
$41.0K
Revenue growth, YoY
+105.0%
Net income, FY2025
-$88.09M
Net margin
-214861.0%
Free cash flow, FY2025
-$67.55M
EPS, diluted, FY2025
-$1.00
Cash
$63.01M
Total debt
$34.74M
P/S
10057.99
Market cap
$412.4M
Annual revenue$41.0K
FY2016FY2025
Annual net income-$88.09M
FY2016FY2025
Annual free cash flow-$67.55M
FY2016FY2025

ALT revenue and earnings growth

ALT revenueQ4 2025$26.0K

Quarter YoY
+420.0%
QoQ
+420.0%
FY YoY
+105.0%
5Y CAGR
-65.3%

ALT revenue was $26.0K in fiscal Q4 2025 (ended Dec 31, 2025), up 420.0% from a year earlier and up 420.0% from the prior quarter. For the full fiscal 2025 it was $41.0K, up 105.0% from fiscal 2024. Compound annual growth was -65.3% over 5 years.

ALT net incomeQ2 2026-$22.82M

ALT net income was -$22.82M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$22.15M a year earlier. For the full fiscal 2025 it was -$88.09M, compared with -$95.06M in fiscal 2024.

ALT EPSQ2 2026-$0.12

ALT diluted EPS was -$0.12 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$1.00, compared with -$1.34 in fiscal 2024.

ALT free cash flowQ2 2026-$24.25M

ALT free cash flow was -$24.25M in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$67.55M.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue$41.0K$20.0K$426.0K-$68.0K$4.41M$8.19M$5.80M$10.33M$10.74M$3.24M
Research and development$66.43M$82.23M$65.80M$70.54M$74.54M$49.77M$17.77M$18.46M$18.41M$7.22M
Selling, general and admin$28.10M$20.97M$18.14M$17.13M$15.41M$13.21M$8.50M$9.77M$8.46M$7.11M
Operating income-$94.49M-$103.17M-$95.93M-$87.74M-$96.91M-$54.80M-$21.46M-$42.83M-$52.05M-$11.09M
Interest expense$1.64M$9.0K$35.0K$8.0K$5.0K$9.4K$2.2K$297.1K$162.1K$38.5K
Pre-tax income-$88.77M-$95.06M-$88.45M-$84.91M-$97.09M-$54.46M-$20.58M-$45.32M-$52.06M-$11.09M
Income tax-$681.0K---$197.0K--$5.42M-$58.5K-$6.15M-$5.64M$0
Net income-$88.09M-$95.06M-$88.45M-$84.71M-$97.09M-$49.04M-$20.52M-$39.17M-$46.43M-$11.09M
EPS, basic-$1.00-$1.34-$1.66-$1.81-$2.35-$1.91-$1.60-$15.16-$118.91-$49.25
EPS, diluted-$1.00-$1.34-$1.66-$1.81-$2.35-$1.91-$1.60-$15.16-$118.91-$49.25
Diluted shares88.1M71.0M53.2M46.9M41.3M25.6M13.1M2.8M431,878232,973.056

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Cash and equivalents$43.76M$36.97M$135.16M$111.13M$190.34M$115.95M$9.00M$34.35M$12.30M$2.88M
Short-term investments$229.70M$94.97M$62.70M$73.78M-$100.01M$28.28M--$66.81M
Current assets$278.19M$137.25M$209.63M$192.81M$204.13M$230.26M$39.39M$39.37M$23.47M$4.49M
Goodwill------$0$0-$18.76M
Total assets$279.93M$139.31M$210.64M$206.93M$218.87M$245.12M$54.06M$54.75M$63.03M$38.40M
Current liabilities$15.00M$10.47M$12.14M$17.05M$18.28M$12.02M$3.92M$4.53M$3.84M$5.47M
Long-term debt$34.29M--$4.58M$1.45M$1.83M$1.86M$1.85M--
Total debt$34.29M--$4.58M$1.45M$1.83M$1.86M$1.85M$599.9K$526.0K
Total liabilities$55.04M$15.80M$16.54M$21.64M$19.73M$19.24M$8.54M$6.44M$14.35M$6.19M
Shareholders' equity$224.89M$123.51M$194.10M$185.29M$199.13M$225.88M$45.52M$48.31M$39.40M$32.21M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Operating cash flow-$67.53M-$79.85M-$75.81M-$62.59M-$78.24M-$34.31M-$9.60M-$9.39M-$20.21M-$6.35M
Capital expenditures$11.0K-$47.0K$126.0K$12.12M$204.0K$1.2K$975.4K$112.4K$125.0K
Free cash flow-$67.55M--$75.86M-$62.71M-$90.36M-$34.51M-$9.60M-$10.36M-$20.33M-$6.48M
Investing cash flow-$132.47M-$28.39M$13.73M-$73.40M$87.52M-$72.23M-$28.29M-$1.00M$13.73M-$220.6K
Financing cash flow$206.84M$10.04M$86.11M$56.78M$65.10M$213.49M$12.53M$32.49M$15.84M$4.98M
Stock-based compensation$16.08M$14.39M$10.64M$8.10M$5.52M$2.58M$1.26M$773.2K$1.44M$965.4K
Depreciation and amortization----$205.0K$551.0K$428.9K$387.3K---

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue growth, YoY105.0%-95.3%--101.5%-46.1%41.1%-43.8%-3.8%231.8%-
Operating margin-230461.0%-515860.0%-22518.5%--2197.6%-669.5%-370.0%-414.6%-484.7%-342.7%
Net margin-214861.0%-475295.0%-20762.2%--2201.6%-599.2%-353.7%-379.2%-432.3%-342.6%
Free cash flow margin-164746.3%--17806.8%--2048.9%-421.6%-165.5%-100.3%-189.3%-200.2%
Return on equity-39.2%-77.0%-45.6%-45.7%-48.8%-21.7%-45.1%-81.1%-117.8%-34.4%
Return on assets-31.5%-68.2%-42.0%-40.9%-44.4%-20.0%-38.0%-71.5%-73.7%-28.9%
Current ratio18.5513.1117.2611.3111.1719.1610.048.706.110.82
Debt to equity0.15--0.020.010.010.040.040.020.02

Source: XBRL data Altimmune Inc. files with the SEC, latest filing dated Aug 12, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures and share counts are restated for stock splits the filings show: 3-for-89, first reported Apr 1, 2019.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

ALT peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
ALT$41.0K+105.0%-$88.09M-214861.0%$412.4M
LLY$86.46B+45.5%$27.58B31.9%$1.33T
JNJ$99.33B+7.8%$16.09B16.2%$679.13B
ABBV$66.01B+10.7%$10.34B15.7%$518.44B
MRK$67.38B+4.9%$2.45B3.6%$366.73B
NVS$54.53B+8.4%$13.98B25.6%$312.35B
AZN$58.74B+8.6%$10.22B17.4%$293.69B
ABT$48.23B+10.0%$4.70B9.7%$191.40B
NVODKK 309.06B+6.4%DKK 102.43B33.1%$183.23B

ALT FAQ

8 questions
  • What is ALT revenue?
    Altimmune Inc. (ALT) reported $41.0K of revenue for fiscal 2025 (ended Dec 31, 2025). That is up 105.0% from the year before.
  • Is ALT profitable?
    No. Altimmune Inc. reported a net loss of $88.09M for fiscal 2025 (ended Dec 31, 2025).
  • How much cash and debt does ALT have?
    Altimmune Inc. reported $63.01M in cash and cash equivalents and $34.74M of debt on its most recent balance sheet in SEC filings.
  • How fast is ALT revenue growing?
    Altimmune Inc.'s revenue changed +105.0% in fiscal 2025, to $41.0K. Its compound annual growth rate was -65.3% over 5 years.
  • What is ALT free cash flow?
    Altimmune Inc. generated -$67.55M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of -$67.53M less capital expenditures.
  • What is ALT earnings per share?
    Diluted earnings per share were -$1.00 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.
  • When did ALT last report financial results?
    The latest statements here come from Altimmune Inc.'s 10-Q filed on Aug 12, 2026, covering the period ended Jun 30, 2026.
  • Where does this ALT financial data come from?
    Quantisnow builds these statements from the structured XBRL data Altimmune Inc. files with the SEC. It is provided for information only and is not investment advice.